


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of the Claims

1-48. (Cancelled)


49. (Currently Amended) An immunologic vaccine comprising as an active component dead cell material derived from PDT-treatment of autologous autoreactive peripheral blood cells, or fragments thereof, or a supernatant thereof, and antigen presenting cells that have not been PDT-treated, wherein said cells the autologous autoreactive peripheral blood cells are treated with a photoactivatable compound selected from the group consisting of:




4,5-dibromorhodamine 123 hydrobromide (2'-(6-amino-4,5-dibromo-3-imino-3H-xanthen-9-yl)-benzoic acid methyl ester hydrobromide),




4,5-dibromorhodamine 123 hydrochloride (2'-(6-amino-4,5-dibromo-3-imino-3H-xanthen-9-yl)-benzoic acid methyl ester hydrochloride),




4,5-dibromorhodamine 110 ethyl ester hydrochloride (2'-(6-amino-4,5-dibromo-3-imino-3H-xanthen-9-yl)benzoic acid ethyl ester hydrochloride),




4,5-dibromorhodamine 110 octyl ester hydrochloride (2'-(6-amino-4,5-dibromo-3-imino-3H-xanthen-9-yl)benzoic acid octyl ester hydrochloride),




4,5-dibromorhodamine 110 n-butyl ester hydrochloride (2'-(6-amino-4,5-dibromo-3-imino-3H-xanthen-9-yl)benzoic acid n-butyl ester hydrochloride),




rhodamine B n-butyl ester hydrochloride (2'-(6-diethyl amino-3-diethyl imino-3H-xanthen-9-yl)benzoic acid n-butyl ester hydrochloride),




4,5-dibromorhodamine 110 ethyl ester hydrobromide (2'-(6-amino-4,5-dibromo-3-imino-3H-xanthen-9-yl)benzoic acid ethyl ester hydrobromide),




4,5-dibromorhodamine 110 octyl ester hydrobromide (2'-(6-amino-4,5-dibromo-3-imino-3H-xanthen-9-yl)benzoic acid octyl ester hydrobromide),




4,5-dibromorhodamine 110 n-butyl ester hydrobromide (2'-(6-amino-4,5-dibromo-3-imino-3H-xanthen-9-yl)benzoic acid n-butyl ester hydrobromide),




4',5'-dichlorotetramethylrhodamine (2'-(6-dimethylamino-3-dimethylimino-3H-xanthen-9-yl)-4',5'-dichloro benzoic acid methyl ester hydrochloride),




4,5-dibromorhodamine 110 2-(2-methoxy ethoxy)ethyl ester hydrobromide (2'-(6-amino-4,5-dibromo-3-imino-3H-xanthen-9-yl)-benzoic acid 2-(2-methoxy ethoxy) ethyl ester hydrobromide),



2,7-dibromorhodamine B hexyl ester acetate (2'-(2,7-dibromo-6-diethyl amino-3-diethylimino-3H-xanthen-9-yl)benzoic acid hexyl ester acetate),




2,7-dibromorhodamine B methyl ester acetate (2'-(2,7-dibromo-6-diethyl amino-3-diethylimino-3H-xanthen 9-yl)benzoic acid methyl ester acetate),




4,5-dibromorhodamine 6G hydrobromide (2'-(4,5-dibromo-2,7-dimethyl-6-ethylamino-3-ethylimino-3H-xanthen-9-yl)benzoic acid ethyl ester hydrobromide),

XV




rhodamine B 3-bromopropylester hydrochloride (2'-(6-diethyl amino-3-diethyl imino-3H-xanthen-9-yl)benzoic acid 3-bromopropyl ester hydrochloride),

XVI




4,5-dibromorhodamine B base (3,3-(4',5'-dibromo-3'-diethyl amino-6'-diethyl aminoxanthen-9'-yl)-3H-isobenzofuran-1-one),

XVII




2,7-dibromorhodamine B base (3,3-(2',7'-dibromo-3'-diethyl amino-6'-diethyl aminoxanthen-9'-yl)-3H-isobenzofuran-1-one), and

XVIII




4-bromo-7-phenyl-rhodamine B base (3,3-(4'-bromo-3'-diethyl amino-6'-diethyl amino-5'-phenyl xanthen-9'-yl)-3H-isobenzofuran-1-one)
and a pharmaceutically acceptable carrier.

50. (Previously Presented) The vaccine of claim 49, wherein said photoactivatable compound is selected from the group consisting of



4,5-dibromorhodamine 123 hydrobromide (2'-(6-amino-4,5-dibromo-3-imino-3H-xanthen-9-yl)-benzoic acid methyl ester hydrobromide) and



4,5-dibromorhodamine 123 hydrochloride (2'-(6-amino-4,5-dibromo-3-imino-3H-xanthen-9-yl)-benzoic acid methyl ester hydrochloride).

51. (Previously Presented) The vaccine of claim 49, wherein said compound is activatable by a light having a wavelength in the range of about 400 to about 800 nm.

52. (Previously Presented) The vaccine of claim 51, wherein said wavelength is in the range of about 450 to about 600 nm.

53-82. (Cancelled)

83. (Currently Amended) ~~An immunological~~ The vaccine according to of claim 49, wherein the vaccine consists of a supernatant of PDT-treated cells.